Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy

Neurology

Volumn 73, Issue 9, 2009, Pages 688-695

  Kuijf, M L ^a   Eurelings, M ^b,c   Tio Gillen, A P ^a   Van Doorn, P A ^a   Van Den Berg, L H ^c   Hooijkaas, H ^a   Stork, J ^c   Notermans, N C ^c   Jacobs, B C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Infection and Immunology   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN ASSOCIATED GLYCOPROTEIN ANTIBODY; PARAGLOBOSIDE; SULFATE 3 GLUCURONYL PARAGLOBOSIDE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ELECTROPHYSIOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGLOBULIN M MONOCLONAL GAMMOPATHY; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; WESTERN BLOTTING;

AUTOANTIBODIES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLOBOSIDES; HUMANS; IMMUNOGLOBULIN M; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MYELIN SHEATH; MYELIN-ASSOCIATED GLYCOPROTEIN; NERVE FIBERS, MYELINATED; PERIPHERAL NERVES; POLYNEUROPATHIES; POLYRADICULONEUROPATHY;

EID: 70349318078     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181b59a80     Document Type: Article

References (34)

1. Latov N. Antibodies to glycoconjugates in neuropathy and motor neuron disease. Prog Brain Res 1994;101:295-303.
2. Quarles RH, Weiss MD. Autoantibodies associated with peripheral neuropathy. Muscle Nerve 1999;22:800-822.
3. Nobile-Orazio E, Manfredini E, Carpo M, et al. Frequency and clinical correlates of antineural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994;36:416-424.
4. van den Berg L, Hays AP, Nobile-Orazio E, et al. Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve 1996;19:637-643.
5. McGarry RC, Helfand SL, Quarles RH, Roder JC. Recognition of myelin-associated glycoprotein by the monoclonal antibody HNK-1. Nature 1983;306:376-378.
6. Weiss MD, Dalakas MC, Lauter CJ, Willison HJ, Quarles RH. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. J Neuroimmunol 1999;95:174-184.
7. Caudie C, Kaygisiz F, Jaquet P, et al. Diagnostic value of autoantibodies to MAG by ELISA Buhlmann in 117 immune-mediated peripheral neuropathies associated with monoclonal IgM to SGPG/SGLPG. Ann Biol Clin (Paris) 2006;64:353-359.
8. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003;49:7-18.
9. Notermans NC, Wokke JH, Franssen H, et al. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry 1993;56:1066-1071.
10. Eurelings M, Lokhorst HM, Kalmijn S, Wokke JH, Notermans NC. Malignant transformation in polyneuropathy associated with monoclonal gammopathy. Neurology 2005;64:2079-2084.
11. Notermans NC, Wokke JH, Lokhorst HM, Franssen H, van der Graaf Y, Jennekens FG. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: a prospective study of the prognostic value of clinical and laboratory abnormalities Brain 1994; 117:1385-1393.
12. Notermans NC, Lokhorst HM, Franssen H, et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology 1996;47:1227-1233.
13. Notermans NC, van Dijk GW, van der Graaf Y, van Gijn J, Wokke JH. Measuring ataxia: quantification based on the standard neurological examination. J Neurol Neurosurg Psychiatry 1994;57:22-26.
14. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:617-618.
15. Eurelings M, Ang CW, Notermans NC, van Doorn PA, Jacobs BC, van den Berg LH. Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy. Neurology 2001;57:1909-1912. (Pubitemid 33096708)
16. Norton WT, Poduslo SE. Myelination in rat brain: method of myelin isolation. J Neurochem 1973;21:749-757.
17. Gabriel JM, Erne B, Bernasconi L, et al. Confocal microscopic localization of anti-myelin-associated glycoprotein autoantibodies in a patient with peripheral neuropathy initially lacking a detectable IgM gammopathy. Acta Neuropathol 1998;95:540-546.
18. Hays AP, Lee SS, Latov N. Immune reactive C3d on the surface of myelin sheaths in neuropathy. J Neuroimmunol 1988;18:231-244.
19. Latov N, Renaud S. Effector mechanisms in anti-MAG antibody-mediated and other demyelinating neuropathies. J Neurol Sci 2004;220:127-129.
20. Mendell JR, Sahenk Z, Whitaker JN, et al. Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin- associated glycoprotein antibody. Ann Neurol 1985;17:243-254.
21. Takatsu M, Hays AP, Latov N, et al. Immunofluorescence study of patients with neuropathy and IgM M proteins. Ann Neurol 1985;18:173-181.
22. Jaskowski TD, Martins TB, Litwin CM, Hill HR. Immunoglobulin (Ig) M antibody against myelin associated glycoprotein (MAG): a comparison of methods. J Clin Lab Anal 2004;18:247-250.
23. Hadden RD, Nobile-Orazio E, Sommer C, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13: 809-818. (Pubitemid 44124676)
24. Garces-Sanchez M, Dyck PJ, Kyle RA, et al. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle Nerve 2008;37:490-495.
25. Lopate G, Kornberg AJ, Yue J, Choksi R, Pestronk A. Anti-myelin associated glycoprotein antibodies: variability in patterns of IgM binding to peripheral nerve. J Neurol Sci 2001;188:67-72.
26. Kohriyama T, Kusunoki S, Ariga T, et al. Subcellular localization of sulfated glucuronic acid-containing glycolipids reacting with anti-myelin-associated glycoprotein antibody. J Neurochem 1987;48:1516-1522.
27. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995; 37:S32-S42.
28. Ritz MF, Erne B, Ferracin F, Vital A, Vital C, Steck AJ. Anti-MAG IgM penetration into myelinated fibers correlates with the extent of myelin widening. Muscle Nerve 1999;22:1030-1037.
29. Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelinassociated glycoprotein. Ann Neurol 1993;33:502-506.
30. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2006;2:CD002827.
31. Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 2006;66:742-744.
32. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999;52:1701-1704.
33. Benedetti L, Briani C, Grandis M, et al. Predictors of response to rituximab in patients with neuropathy and antimyelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 2007;2:102-107.
34. Benedetti L, Briani C, Franciotta D, et al. Long-term effect of rituximab in anti-mag polyneuropathy. Neurology 2008;71:1742-1744.